Plaque Psoriasis Patients Benefit From Foam Treatment


A real-world study found that the formulation of calcipotriene 0.005% with betamethasone dipropionate 0.064% (Cal/BD) foam effectively relieved pruritus and improved skin clearance among patients with plaque psoriasis, according to a poster study presented at the Winter Clinical Dermatology Conference in Maui, Hawaii.

In the retrospective study, the researchers assessed clinical characteristics of 105 patients with plaque psoriasis who were treated with Cal/BD foam at clinical practices in the United States (mean age 41.7 years, 88% were White). They examined prescription patterns and adverse events associated with the foam. In addition, the researchers sent surveys to health care providers to assess their thoughts on Cal/BD.

Patients had a history of plaques that affected the knees, elbows, trunk, lower extremities, upper extremities, and scalp. Overall, 45.7% of patients reported itch to their health care provider and 60.4% of patients reported that itch affected their quality of life.

A total of 177 plaque areas were treated with Cal/BD foam, which was used once a day for 4 weeks. Prior to initiating treatment, 113 plaques had been classified as either mild, moderate, or severe.

After 4 weeks of treatment, 70.6% of plaques that were classified as mild, moderate, or severe at baseline were ‘clear’ or ‘almost clear’ and 55.7% of plaques that were mild, moderate, or severe at baseline were ‘clear’ or ‘almost clear’ with 2-grade improvement. In addition, Cal/BD resolved itch for 90.1% of plaques with itch at baseline and did not cause pruritus on plaques without itch. Only one patient experienced skin irritation on the knees, palms of hands, and soles of feet.

“Based on this chart review study, adult psoriasis patients treated topically with Cal/BD foam for up to 4 weeks realized significant improvements in treatment response of plaque lesions. Lesions were ‘clear’ or ‘almost clear’ and with important corresponding reductions of itch,” the researchers concluded. “These data help extend results reported from clinical trials with Cal/BD foam.”

—Melissa Weiss


Wu JJ, Veverka KA, Lu M, Armstrong AW. Real world experienced with calcipotriene and betamethasone dipropionate foam 0.005%/0.064% (CalBD foam) in the treatment of adult psoriasis itch from retrospective chart review. Presented at: The Winter Clinical Dermatology Conference; January 12-17, 2018; Maui, Hawaii.